This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (78)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Radiation Therapy  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Youn H. Kim, MD; Steve Chow, BS; Anna Varghese, BA; Richard T. Hoppe, MD

Arch Dermatol. 1999;135:26-32.

Objectives  To study the long-term results of treatment of patients with generalized patch and/or plaque mycosis fungoides and to identify clinical characteristics predictive of survival and response to treatment.

Design  A single-center, 35.5-year retrospective cohort analysis.

Setting  Private referral medical center.

Patients  One hundred seventy-six patients with generalized patch and/or plaque (T2) mycosis fungoides.

Main Outcome Measures  Long-term actuarial survival and freedom-from-relapse results as calculated by the Kaplan-Meier method.

Results  The long-term (35.5-year) survival of patients with T2 mycosis fungoides is worse than the expected survival of a race-, age-, and sex-matched control population (P<.001). The median survival of the T2 group is 11.7 years. Patients younger than 58 years (median age) at presentation have a more favorable overall and disease-specific survival than the patients who are 58 years or older (P<.001 vs P<.025). Patient sex or race had no significant effect on overall survival. Patients who presented with palpable clinically significant lymph nodes (stage IIA) had long-term survival results similar to those without lymphadenopathy (stage IB), despite improved freedom-from-relapse outcome for patients with stage IB. Twenty-four percent of patients who progressed to more advanced disease had a lower complete response rate to initial therapy than did other patients (21% vs 65%) (P<.001). Patients who received total skin electron beam therapy had a better complete response rate than patients treated with topical mechlorethamine hydrochloride alone; the relapse-free results were superior in patients with a total dose of 30 Gy or higher and in patients who received topical mechlorethamine as adjuvant therapy following total skin electron beam therapy. Despite differences in freedom-from-relapse results among different treatment groups, long-term overall or disease-specific survivals were not significantly different.

Conclusions  A significant proportion (24%) of patients with generalized patch and/or plaque (T2) mycosis fungoides experience disease progression to a more advanced clinical stage, and nearly 20% eventually die of the disease. Younger patients have a more favorable disease-specific long-term outcome than patients who are older. Presence of lymphadenopathy (stage IIA) at diagnosis does not predict worse long-term survival outcome. Clinical features predictive of disease progression include initial lymphadenopathy (stage IIA) and lack of complete response to initial treatment. Despite superior complete response rate to a 30-Gy or higher dose of total skin electron beam therapy, topical mechlorethamine proves to be a cost-effective initial treatment for patients with T2 disease. The concept of an adjuvant therapy after irradiation is appealing, although it may not lead to improved long-term survival.

From the Departments of Dermatology (Dr Kim and Mr Chow) and Radiation Oncology (Ms Varghese and Dr Hoppe), Stanford University School of Medicine, Stanford, Calif.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(1):106.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Kim et al.
Blood 2007;109:4655-4662.
ABSTRACT | FULL TEXT  

Analysis of T-Cell Receptor Gene Rearrangement for Predicting Clinical Outcome in Patients With Cutaneous T-Cell Lymphoma: A Comparison of Southern Blot and Polymerase Chain Reaction Methods
Juarez et al.
Arch Dermatol 2005;141:1107-1113.
ABSTRACT | FULL TEXT  

Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids: A Prospective Study
de Quatrebarbes et al.
Arch Dermatol 2005;141:1117-1120.
ABSTRACT | FULL TEXT  

Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy
Querfeld et al.
Arch Dermatol 2005;141:305-311.
ABSTRACT | FULL TEXT  

Early TCR-{beta} and TCR-{gamma} PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications
Assaf et al.
Blood 2005;105:503-510.
ABSTRACT | FULL TEXT  

Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT | FULL TEXT  

Long-term Outcome of 525 Patients With Mycosis Fungoides and Sezary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression
Kim et al.
Arch Dermatol 2003;139:857-866.
ABSTRACT | FULL TEXT  

Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma
Kari et al.
JEM 2003;197:1477-1488.
ABSTRACT | FULL TEXT  

Phase 1/2 Pilot Study of Methotrexate-Laurocapram Topical Gel for the Treatment of Patients With Early-Stage Mycosis Fungoides
Demierre et al.
Arch Dermatol 2003;139:624-628.
ABSTRACT | FULL TEXT  

Topical Nitrogen Mustard in the Management of Mycosis Fungoides: Update of the Stanford Experience
Kim et al.
Arch Dermatol 2003;139:165-173.
ABSTRACT | FULL TEXT  

Lymphoma of the Skin
Connors et al.
ASH Education Book 2002;2002:263-282.
ABSTRACT | FULL TEXT  

Fas Ligand Expression by Neoplastic T Lymphocytes Mediates Elimination of CD8+ Cytotoxic T Lymphocytes in Mycosis Fungoides: A Potential Mechanism of Tumor Immune Escape?
Ni et al.
Clin. Cancer Res. 2001;7:2682-2692.
ABSTRACT | FULL TEXT  

Update in Dermatology
Kazin et al.
ANN INTERN MED 2001;135:124-132.
FULL TEXT  

Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
Duvic et al.
JCO 2001;19:2456-2471.
ABSTRACT | FULL TEXT  

Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Duvic et al.
Arch Dermatol 2001;137:581-593.
ABSTRACT | FULL TEXT  

Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides
de Coninck et al.
JCO 2001;19:779-784.
ABSTRACT | FULL TEXT  

Narrowband TL-01 Phototherapy for Patch-Stage Mycosis Fungoides
Clark et al.
Arch Dermatol 2000;136:748-752.
ABSTRACT | FULL TEXT  

Mycosis Fungoides: Disease Evolution and Prognosis of 309 Dutch Patients
van Doorn et al.
Arch Dermatol 2000;136:504-510.
ABSTRACT | FULL TEXT  

Treatment of Multifocal Primary Cutaneous B-Cell Lymphoma: A Clinical Follow-Up Study of 29 Patients
Bekkenk et al.
JCO 1999;17:2471-2471.
ABSTRACT | FULL TEXT  

An Update on Treating Cutaneous T-Cell Lymphoma
Journal Watch Dermatology 1999;1999:10-10.
FULL TEXT  

Shortened Survival for Patients with Stage T2 Mycosis Fungoides
Journal Watch Dermatology 1999;1999:3-3.
FULL TEXT